T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients
T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients
复制标题
DOI：
10.1016/j.clim.2004.06.004
复制
发表时间：
2004-11-01
影响因子：
8.6
通讯作者：
Mandel, M
中科院分区：
文献类型：
--
作者：
Achiron, A;Lavie, G;Mandel, M
髓磷脂自身反应性T细胞参与多发性硬化（MS）的发病机制并导致疾病的传播。我们评估了T细胞疫苗（TCV）治疗免疫调节治疗无效的侵袭性复发缓解型MS患者的疗效。20例无应答复发缓解型MS患者在用合成髓鞘碱性蛋白（MBP）和髓鞘少突胶质细胞糖蛋白（MOG）致脑炎肽活化后，用自体减毒T细胞系免疫。每名患者每隔6至8周接种三次疫苗。年复发率从2.6下降到1.1，P=0.026。与治疗前2年和1年的进展率相比，神经功能障碍稳定。通过定量MRI分析证实了活动性病变数量和体积的显著减少以及T2病变负荷的减少。未观察到严重不良事件。我们的研究结果表明，TCV在MS患者中具有有益的临床效果，尽管进行了免疫调节治疗，但仍继续恶化。TCV可作为该亚组无应答患者的潜在替代治疗。(C)2004年爱思唯尔公司All rights reserved.
Myelin autoreactive T cells are involved in the pathogenesis of multiple sclerosis (MS) and lead to propagation of the disease. We evaluated the efficacy of T cell vaccination (TCV) therapy for patients with aggressive relapsing-remitting MS who failed to respond to immunomodulatory treatments. Twenty nonresponders relapsing-remitting MS patients were immunized with autologous attenuated T cell lines after activation with synthetic myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) encephalitogenic peptides. Each patient received three vaccinations in 6- to 8-week intervals. Annual relapse rate decreased from 2.6 to 1.1, P=0.026. Neurological disability stabilized as compared with the 2- and 1-year pretreatment progression rates. Significant reduction in the number and volume of active lesions, as well as reduction in T2 lesion burden, was demonstrated by quantitative MRI analysis. No serious adverse events were observed. Our findings suggest that TCV has beneficial clinical effects in MS patients who, in spite of immunomodulatory treatments, continue to deteriorate. TCV Could serve as a potential alternative therapy for this subgroup of nonresponders patients. (C) 2004 Elsevier Inc. All rights reserved.